Complementary and Integrated Medicine Research Unit, Primary Medical Care, Aldermoor Health Centre, Aldermoor Close, Southampton SO16 5ST, UK.
Rheumatology (Oxford). 2011 Jun;50(6):1070-82. doi: 10.1093/rheumatology/keq234. Epub 2010 Nov 13.
To assess whether any benefits from adjunctive homeopathic intervention in patients with RA are due to the homeopathic consultation, homeopathic remedies or both.
Exploratory double-blind, randomized placebo-controlled trial conducted from January 2008 to July 2008, in patients with active stable RA receiving conventional therapy. Eighty-three participants from three secondary care UK outpatient clinics were randomized to 24 weeks of treatment with either homeopathic consultation (further randomized to individualized homeopathy, complex homeopathy or placebo) or non-homeopathic consultation (further randomized to complex homeopathy or placebo). Co-primary outcomes: ACR 20% improvement (ACR20) criteria and patient monthly global assessment (GA).
28-joint DAS (DAS-28), tender and swollen joint count, disease severity, pain, weekly patient and physician GA and pain, and inflammatory markers.
Fifty-six completed treatment phase. No significant differences were observed for either primary outcome. There was no clear effect due to remedy type. Receiving a homeopathic consultation significantly improved DAS-28 [mean difference 0.623; 95% CI 0.1860, 1.060; P = 0.005; effect size (ES) 0.70], swollen joint count (mean difference 3.04; 95% CI 1.055, 5.030; P = 0.003; ES 0.83), current pain (mean difference 9.12; 95% CI 0.521, 17.718; P = 0.038; ES 0.48), weekly pain (mean difference 6.017; 95% CI 0.140, 11.894; P = 0.045; ES 0.30), weekly patient GA (mean difference 6.260; 95% CI 0.411, 12.169; P = 0.036; ES 0.31) and negative mood (mean difference - 4.497; 95% CI -8.071, -0.923; P = 0.015; ES 0.90).
Homeopathic consultations but not homeopathic remedies are associated with clinically relevant benefits for patients with active but relatively stable RA.
Current controlled trials, http://www.controlled-trials.com/, ISRCTN09712705.
评估辅助顺势疗法干预对类风湿关节炎患者的益处是否归因于顺势疗法咨询、顺势疗法疗法或两者兼而有之。
这是一项从 2008 年 1 月至 2008 年 7 月进行的探索性、双盲、随机安慰剂对照试验,纳入正在接受常规治疗的活动性稳定类风湿关节炎患者。来自英国三家二级保健门诊的 83 名参与者被随机分配至 24 周的顺势疗法咨询治疗(进一步随机分配至个体化顺势疗法、复方顺势疗法或安慰剂)或非顺势疗法咨询治疗(进一步随机分配至复方顺势疗法或安慰剂)。主要结局指标:ACR20%改善(ACR20)标准和患者每月整体评估(GA)。
28 关节 DAS(DAS-28)、压痛和肿胀关节计数、疾病严重程度、疼痛、每周患者和医生 GA 以及疼痛和炎症标志物。
56 名患者完成了治疗阶段。主要结局指标均无显著差异。治疗方法类型也没有明显的效果。接受顺势疗法咨询显著改善了 DAS-28[平均差异 0.623;95%置信区间 0.1860,1.060;P=0.005;效应量(ES)0.70]、肿胀关节计数(平均差异 3.04;95%置信区间 1.055,5.030;P=0.003;ES 0.83)、当前疼痛(平均差异 9.12;95%置信区间 0.521,17.718;P=0.038;ES 0.48)、每周疼痛(平均差异 6.017;95%置信区间 0.140,11.894;P=0.045;ES 0.30)、每周患者 GA(平均差异 6.260;95%置信区间 0.411,12.169;P=0.036;ES 0.31)和负性情绪(平均差异-4.497;95%置信区间-8.071,-0.923;P=0.015;ES 0.90)。
对于活动性但相对稳定的类风湿关节炎患者,顺势疗法咨询而非顺势疗法疗法与临床相关益处相关。